Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 2,828 shares of the business's stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $35.04, for a total value of $99,093.12. Following the completion of the transaction, the insider owned 32,737 shares in the company, valued at $1,147,104.48. The trade was a 7.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Price Performance
CSTL stock opened at $34.50 on Friday. The company has a quick ratio of 5.12, a current ratio of 5.28 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $34.33 and a 200-day moving average of $28.37. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The business had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.76 million. On average, sell-side analysts predict that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Castle Biosciences
Several institutional investors have recently bought and sold shares of CSTL. Allworth Financial LP lifted its stake in Castle Biosciences by 255.3% in the third quarter. Allworth Financial LP now owns 938 shares of the company's stock valued at $33,000 after purchasing an additional 674 shares during the last quarter. NFSG Corp purchased a new stake in Castle Biosciences in the third quarter worth $36,000. Global Retirement Partners LLC purchased a new stake in Castle Biosciences in the second quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Castle Biosciences in the third quarter valued at $55,000. Finally, Quantbot Technologies LP bought a new stake in shares of Castle Biosciences in the second quarter valued at $62,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on CSTL shares. Wall Street Zen raised Castle Biosciences from a "hold" rating to a "buy" rating in a research report on Sunday, November 1st. KeyCorp boosted their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, November 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Castle Biosciences in a research report on Thursday, October 29th. Robert W. Baird raised their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Mizuho assumed coverage on shares of Castle Biosciences in a report on Thursday, October 29th. They set an "outperform" rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Castle Biosciences currently has an average rating of "Moderate Buy" and an average target price of $46.50.
View Our Latest Stock Analysis on CSTL
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company's portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett's esophagus.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
